[an error occurred while processing this directive] | [an error occurred while processing this directive]
Translational study and clinical application of precision medicine in nasopharyngeal carcinoma
Yin Jun,Xu Peng,Qin Yuan,Lang Jinyi
Department of Radiation Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center;School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China
Abstract The application of precision medicine in cancer treatment is becoming increasingly common as a result of the continuous advancement in basic research and physical techniques. The revolution of radiotherapy techniques, development of multimodal imaging technology, application of biological target dose carving and adaptive radiotherapy, availability of big data-based radiotherapy planning systems, and selection of chemotherapy regimen have all made the treatment of nasopharyngeal carcinoma increasingly precise. The growing interaction between laboratory research and clinical practice not only underscores the importance of translational medicine, but also prompts the development of biological immunotherapy and screening of prognostic factors. As a result, these changes mark the beginning of a new era for the diagnosis and treatment of nasopharyngeal carcinoma. This review provides a summary from 61 articles on the current progress in translational study and clinical application of precision medicine in nasopharyngeal carcinoma.
Fund:Support Program by Science and Technology Bureau of Sichuan Province (2015SZ0053)
Corresponding Authors:
Lang Jinyi,Email:langjy610@163.com
Cite this article:
Yin Jun,Xu Peng,Qin Yuan et al. Translational study and clinical application of precision medicine in nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(7): 823-827.
Yin Jun,Xu Peng,Qin Yuan et al. Translational study and clinical application of precision medicine in nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(7): 823-827.
[1] Lee N,Harris J,Garden AS,et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma:radiation therapy oncology group phase Ⅱ trial 0225[J].J Clin Oncol,2009,27(22):3684-3690.DOI:10.1200/jco.2008.19.9109. [2] Wong FCS,Ng AWY,Lee VHF,et al. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2010,76(1):138-145.DOI:10.1016/j.ijrobp.2009.01.084. [3] Peng G,Wang T,Yang KY,et al. A prospective,randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs.conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J].Radiother Oncol,2012,104(3):286-293.DOI:10.1016/j.radonc.2012.08.013. [4] Sun XM,Su SF,Chen CY,et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma:an analysis of survival and treatment toxicities[J].Radiother Oncol,2014,110(3):398-403.DOI:10.1016/j.radonc.2013.10.020. [5] Lim TC,Chua ML,Chia GS,et al. Comparison of MRI,CT and 18F-FDG-PET/CT for the detection of intracranial disease extension in nasopharyngeal carcinoma[J].Head Neck Oncol,2012,4(2):49. [6] Lee TF,Fang FM,Chao PJ,et al. Dosimetric comparisons of helical tomotherapy and step-and-shoot intensity-modulated radiotherapy in nasopharyngeal carcinoma[J].Radiother Oncol,2008,89(1):89-96.DOI:10.1016/j.radonc.2008.05.010. [7] Du L,Zhang XX,Ma L,et al. Clinical study of nasopharyngeal carcinoma treated by helical tomotherapy in China:5-year outcomes[J].Biomed Res Int,2014,2014:980767.DOI:10.1155/2014/980767. [8] Puebla F,Lopez-Guerra JL,Garcia-Ramirez JM,et al. Effectiveness and toxicity of helical tomotherapy for patients with locally recurrent nasopharyngeal carcinoma[J].Clin Transl Oncol,2015,17(11):925-931.DOI:10.1007/s12094-015-1328-5. [9] Yoon HI,Kim KH,Lee J,et al. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography (PET) to predict oncologic outcomes and PET-based radiotherapeutic considerations in locally advanced nasopharyngeal carcinoma[J].Cancer Res Treat,2016,48(3):928-941.DOI:10.4143/crt.2015.275. [10] Bradshaw TJ,Bowen SR,Deveau MA,et al. Molecular imaging biomarkers of resistance to radiation therapy for spontaneous nasal tumors in canines[J].Int J Radiat Oncol Biol Phys,2015,91(4):787-795.DOI:10.1016/j.ijrobp.2014.12.011. [11] Nyflot MJ,Kruser TJ,Traynor AM,et al. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia,proliferation,and perfusion[J].Int J Radiat Oncol Biol Phys,2015,91(5):942-951.DOI:10.1016/j.ijrobp.2014.11.029. [12] Choi W,Lee SW,Park SH,et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer[J].Radiother Oncol,2010,97(2):176-182.DOI:10.1016/j.radonc.2010.04.012. [13] Yasuda K,Onimaru R,Okamoto S,et al.[18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer[J].Int J Radiat Oncol Biol Phys,2013,85(1):142-147.DOI:10.1016/j.ijrobp.2012.03.029. [14] Chuang CH,Chuang KH,Wang HE,et al. In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate[J].Clin Cancer Res,2012,18(1):238-247.DOI:10.1158/1078-0432.ccr-11-0608. [15] Huang BS,Wong CS,Whitcher B,et al. Dynamic contrast-enhanced magnetic resonance imaging for characterising nasopharyngeal carcinoma:comparison of semiquantitative and quantitative parameters and correlation with tumour stage[J].Eur Radiol,2013,23(6):1495-1502.DOI:10.1007/s00330-012-2740-7. [16] Zheng DC,Chen YB,Chen Y,et al. Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma:a preliminary study of the correlations between quantitative parameters and clinical stage[J].J Magn Reson Imaging,2014,39(4):940-948.DOI:10.1002/jmri.24249. [17] 吕衍春,范卫君,李娴,等.MR波谱在鼻咽癌放疗后颅底复发与放射性脑病鉴别诊断中的应用[J].中华放射学杂志,2008,42(7):714-719.DOI:10.3321/j.issn:1005-1201.2008.07.010. Lyu YC,Fan WJ,Li X,et al. Application of MR spectrum in differential diagnosis of skull base recurrence and radiation encephalopathy after radiotherapy for nasopharyngeal carcinoma[J].Chin J Radiol,2008,42(7):714-719.DOI:10.3321/j.issn:1005-1201.2008.07.010. [18] Surucu M,Shah KK,Mescioglu I,et al. Decision trees predicting tumor shrinkage for head and neck cancer:implications for adaptive radiotherapy[J].Technol Cancer Res Treat,2015.DOI:10.1177/1533034615572638. [19] Zschaeck S,Haase R,Abolmaali N,et al. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure[J].Acta Oncol,2015,54(9):1355-1363.DOI:10.3109/0284186x.2015.1074720. [20] Chang JH,Wada M,Anderson NJ,et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using 18F-FMISO PET:a biological modeling study[J].Acta Oncol,2013,52(8):1723-1729.DOI:10.3109/0284186x.2012.759273. [21] Korreman SS,Ulrich S,Bowen S,et al. Feasibility of dose painting using volumetric modulated arc optimization and delivery[J].Acta Oncol,2010,49(7):964-971.DOI:10.3109/0284186x.2010.498440. [22] Deveau MA,Bowen SR,Westerly DC,et al. Feasibility and sensitivity study of helical tomotherapy for dose painting plans[J].Acta Oncol,2010,49(7):991-996.DOI:10.3109/0284186x.2010.500302. [23] Chitapanarux I,Chomprasert K,Nobnaop W,et al. A dosimetric comparison of two-phase adaptive intensity-modulated radiotherapy for locally advanced nasopharyngeal cancer[J].J Radiat Res,2015,56(3):529-538.DOI:10.1093/jrr/rru119. [24] Schwartz DL,Garden AS,Thomas J,et al. Adaptive radiotherapy for head-and-neck cancer:initial clinical outcomes from a prospective trial[J].Int J Radiat Oncol Biol Phys,2012,83(3):986-993.DOI:10.1016/j.ijrobp.2011.08.017. [25] Nishimura Y,Shibata T,Nakamatsu K,et al. A two-step intensity-modulated radiation therapy method for nasopharyngeal cancer:the Kinki University experience[J].Jpn J Clin Oncol,2010,40(2):130-138.DOI:10.1093/jjco/hyp136. [26] Ma BBY,Kam MKM,Leung SF,et al. A phase Ⅱ study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma[J].Ann Oncol,2012,23(5):1287-1292.DOI:10.1093/annonc/mdr401. [27] Chan ATC,Hsu MM,Goh BC,et al. Multicenter,phase Ⅱ study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma[J].J Clin Oncol,2005,23(15):3568-3576.DOI:10.1200/jco.2005.02.147. [28] Xu T,Liu Y,Dou S,et al. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma:results of a randomized phase Ⅱ study[J].Oral Oncol,2015,51(9):875-879.DOI:10.1016/j.oraloncology.2015.06.008. [29] Lee NY,Zhang Q,Pfister DG,et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615):a phase 2 multi-institutional trial[J].Lancet Oncol,2012,13(2):172-180.DOI:10.1016/s1470-2045(11)70303-5. [30] Hui EP,Ma BBY,King AD,et al. Hemorrhagic complications in a phase Ⅱ study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation[J].Ann Oncol,2011,22(6):1280-1287.DOI:10.1093/annonc/mdq629. [31] Lim WT,Ng QS,Ivy P,et al. A phase Ⅱ study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma[J].Clin Cancer Res,2011,17(16):5481-5489.DOI:10.1158/1078-0432.ccr-10-3409. [32] Leung SF,Zee B,Ma BB,et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma[J].J Clin Oncol,2006,24(34):5414-5418.DOI:10.1200/jco.2006.07.7982. [33] An X,Wang FH,Ding PR,et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy[J].Cancer,2011,117(16):3750-3757.DOI:10.1002/cncr.25932. [34] Lin JC,Wang WY,Chen KY,et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma[J].N Engl J Med,2004,350(24):2461-2470.DOI:10.1056/NEJMoa032260. [35] Chan ATC,Lo YM,Zee B,et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma[J].J Natl Cancer Inst,2002,94(21):1614-1619.DOI:10.1093/jnci/94.21.1614. [36] Le QT,Zhang Q,Cao HB,et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma[J].Clin Cancer Res,2013,19(8):2208-2215.DOI:10.1158/1078-0432.ccr-12-3702. [37] Lee AWM,Ma BBY,Ng WT,et al. Management of nasopharyngeal carcinoma:current practice and future perspective[J].J Clin Oncol,2015,33(29):3356-3364.DOI:10.1200/JCO.2015.60.9347. [38] Ghosh SK,Perrine SP,Faller DV.Advances in virus-directed therapeutics against Epstein-Barr virus-associated malignancies[J].Adv Virol,2012,2012:509296.DOI:10.1155/2012/509296. [39] Khanna R,Moss D,Gandhi M.Technology insight:applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies[J].Nat Clin Pract Oncol,2005,2(3):138-149.DOI:10.1038/ncponc0107. [40] Chia WK,Teo M,Wang WW,et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma[J].Mol Ther,2014,22(1):132-139.DOI:10.1038/mt.2013.242. [41] Chia WK,Wang WW,Teo M,et al. A phase Ⅱ study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma[J].Ann Oncol,2012,23(4):997-1005.DOI:10.1093/annonc/mdr341. [42] Hui EP,Taylor GS,Jia H,et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients[J].Cancer Res,2013,73(6):1676-1688.DOI:10.1158/0008-5472.can-12-2448. [43] Hsu MC,Hsiao JR,Chang KC,et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma[J].Mod Pathol,2010,23(10):1393-1403.DOI:10.1038/modpathol.2010.130. [44] Fang WF,Zhang JW,Hong SD,et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma:implications for oncotargeted therapy[J].Oncotarget,2014,5(23):12189-12202.DOI:10.18632/oncotarget.2608. [45] Wu X,Huang PY,Peng PJ,et al. Long-term follow-up of a phase Ⅲ study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma[J].Ann Oncol,2013,24(8):2131-2136.DOI:10.1093/annonc/mdt163. [46] Loong HH,Ma BBY,Leung SF,et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma[J].Radiother Oncol,2012,104(3):300-304.DOI:10.1016/j.radonc.2011.12.022. [47] Lee AWM,Tung SY,Ngan RKC,et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma:combined analyses of NPC-9901 and NPC-9902 Trials[J].Eur J Cancer,2011,47(5):656-666.DOI:10.1016/j.ejca.2010.10.026. [48] Chen Y,Sun Y,Liang SB,et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage Ⅲ to IVB nasopharyngeal carcinoma from endemic regions of China[J].Cancer,2013,119(12):2230-2238.DOI:10.1002/cncr.28049. [49] Blanchard P,Lee A,Marguet S,et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma:an update of the MAC-NPC meta-analysis[J].Lancet Oncol,2015,16(6):645-655.DOI:10.1016/s1470-2045(15)70126-9. [50] Hui EP,Ma BB,Leung SF,et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma[J].J Clin Oncol,2009,27(2):242-249.DOI:10.1200/jco.2008.18.1545. [51] Sun Y,Li WF,Chen NY,et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:a phase 3,multicentre,randomised controlled trial[J].Lancet Oncol,2016,17(11):1509-1520.DOI:10.1016/s1470-2045(16)30410-7. [52] Tan T,Lim WT,Fong KW,et al. Concurrent chemo-radiation with or without induction gemcitabine,Carboplatin,and Paclitaxel:a randomized,phase 2/3 trial in locally advanced nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2015,91(5):952-960.DOI:10.1016/j.ijrobp.2015.01.002. [53] Fountzilas G,Ciuleanu E,Bobos M,et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma:a randomized phase Ⅱ study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation[J].Ann Oncol,2012,23(2):427-435.DOI:10.1093/annonc/mdr116. [54] Chen L,Hu CS,Chen XZ,et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma:a phase 3 multicentre randomised controlled trial[J].Lancet Oncol,2012,13(2):163-171.DOI:10.1016/s1470-2045(11)70320-5. [55] Teguh DN,Levendag PC,Voet PWJ,et al. Clinical validation of atlas-based auto-segmentation of multiple target volumes and normal tissue (swallowing/mastication) structures in the head and neck[J].Int J Radiat Oncol Biol Phys,2011,81(4):950-957.DOI:10.1016/j.ijrobp.2010.07.009. [56] Voet PWJ,Dirkx MLP,Teguh DN,et al. Does atlas-based autosegmentation of neck levels require subsequent manual contour editing to avoid risk of severe target underdosage? A dosimetric analysis[J].Radiother Oncol,2011,98(3):373-377.DOI:10.1016/j.radonc.2010.11.017. [57] Sims R,Isambert A,Grégoire V,et al. A pre-clinical assessment of an atlas-based automatic segmentation tool for the head and neck[J].Radiother Oncol,2009,93(3):474-478.DOI:10.1016/j.radonc.2009.08.013. [58] Thomson D,Boylan C,Liptrot T,et al. Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk[J].Radiat Oncol,2014,9:173.DOI:10.1186/1748-717x-9-173. [59] Moore KL,Brame RS,Low DA,et al. Experience-based quality control of clinical intensity-modulated radiotherapy planning[J].Int J Radiat Oncol Biol Phys,2011,81(2):545-551.DOI:10.1016/j.ijrobp.2010.11.030. [60] Good D,Lo J,Lee WR,et al. A knowledge-based approach to improving and homogenizing intensity modulated radiation therapy planning quality among treatment centers:an example application to prostate cancer planning[J].Int J Radiat Oncol Biol Phys,2013,87(1):176-181.DOI:10.1016/j.ijrobp.2013.03.015. [61] Schmidt M,Lo JY,Grzetic S,et al. Semiautomated head-and-neck IMRT planning using dose warping and scaling to robustly adapt plans in a knowledge database containing potentially suboptimal plans[J].Med Phys,2015,42(8):4428-4434.DOI:10.1118/1.4923174.
2017, Vol. 26 
